In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage regarding the FDA’s effort to revoke its approval of avacopan for ANCA-associated vasculitis.
The FDA has alleged that employees of the drug’s original manufacturer, ChemoCentryx, manipulated data in the ADVOCATE trial, which was the sole study the FDA considered before approving avacopan (Tavneos, Amgen) in 2021. The New England Journal of Medicine has since retracted its publication of the ADVOCATE trial at the request of the study’s academic